RPRX
It's going to be an interesting battle between the January effect, the outcomes of the analyst meeting (there's gotta be some upgrades after that), the potential financing, any Androxal news, takeover talk, profit taking, and the results for the key secondary end point of fibroid volume.
In short, you may, or may not, see a transient buying opportunity on Wednesday.